EUVIMEDOpdag EUVIMED
Crossref

Adjuvant Radiotherapy for Early‐Stage Oral Tongue Cancer: Insights From the NCDB Based on Grade

Bryan Nolasco iD, N Patrik Brodin, Nina Samuel, Bradley Schiff, Vikas Mehta, Madhur Garg, Rafi Kabarriti

Head & Neck · 2025

DOI: 10.1002/hed.28243 ↗

At a glance

Journal article in Head & Neck, 2025. Written by Bryan Nolasco and 6 co-authors. Institution: Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA. Major MEDLINE topics: Tongue Neoplasms. 16 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Oral tongue squamous cell carcinoma (OTSCC) incidence is rising in the United States. While early‐stage (pT1‐2N0M0) OTSCC is primarily managed with surgery, the role of postoperative radiotherapy (PORT) remains debated, particularly in moderate‐to‐poor differentiation. Current guidelines do not recommend PORT based on histologic grade alone, yet a retrospective study by Tian et al. found PORT improved survival in moderately‐to‐poorly differentiated OTSCC in a Chinese cohort. We aimed to validate these findings in a US population.

Methods

A retrospective cohort study using the National Cancer Database (2004–2022) identified patients with pT1‐2N0M0 OTSCC treated with surgery or surgery plus PORT. After stringent inclusion criteria, 3562 patients remained, including 456 (12.8%) who received PORT. Propensity score matching (PSM) balanced key prognostic factors, and survival was assessed using Kaplan–Meier analysis and multivariable Cox proportional hazards models.

Results

PORT did not improve OS in well‐ or moderately differentiated tumors. However, in poorly differentiated tumors, PORT was associated with a significant survival benefit (HR: 0.53, 95% CI: 0.30–0.92, p = 0.025) before and after PSM. This effect persisted in multivariable analysis (HR: 0.56, 95% CI: 0.31–0.99, p = 0.047) and after excluding patients with lymphovascular invasion (HR: 0.48, 95% CI: 0.27–0.87, p = 0.016).

Conclusions

These findings validate and extend prior international data, demonstrating a PORT‐associated survival benefit in poorly differentiated early‐stage OTSCC. The lack of benefit in well‐ and moderately differentiated tumors underscores the need for individualized treatment approaches. Prospective studies are warranted to refine risk stratification and optimize clinical guidelines.

Subjects

MeSH terms (MEDLINE)

Tongue NeoplasmsHumansFemaleMaleRetrospective StudiesRadiotherapy, AdjuvantMiddle AgedAgedNeoplasm StagingUnited StatesNeoplasm GradingDatabases, FactualPropensity ScoreAdultKaplan-Meier Estimate

Author keywords

adjuvant treatmenthead and neck cancerhistologic differentiationoral tongue squamous cell carcinomapostoperative radiotherapysurvival analysistreatment outcomes

Authors and institutions

  • Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
  • Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York, USA.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center, Bronx, New York, USA.

ORCID profiles: Bryan Nolasco

Cite

APA

Nolasco, B., Brodin, N. P., Samuel, N., Schiff, B., Mehta, V., Garg, M., & Kabarriti, R. (2025). Adjuvant Radiotherapy for Early‐Stage Oral Tongue Cancer: Insights From the NCDB Based on Grade. Head & Neck. https://doi.org/10.1002/hed.28243

Vancouver

Nolasco B, Brodin NP, Samuel N, Schiff B, Mehta V, Garg M, et al. Adjuvant Radiotherapy for Early‐Stage Oral Tongue Cancer: Insights From the NCDB Based on Grade. Head & Neck. 2025. doi:10.1002/hed.28243

BibTeX
@article{Nolasco2025,
  author = {Nolasco, Bryan and Brodin, N Patrik and Samuel, Nina and Schiff, Bradley and Mehta, Vikas and Garg, Madhur and Kabarriti, Rafi},
  title = {Adjuvant Radiotherapy for Early‐Stage Oral Tongue Cancer: Insights From the NCDB Based on Grade},
  journal = {Head & Neck},
  year = {2025},
  doi = {10.1002/hed.28243}
}
Start for free →